Straits Times Index
3,285.95 -1.80 (-0.05%) Nikkei
37,900.61 +272.13 (+0.72%) Hang Seng
17,616.45 +331.91 (+1.92%) FTSE 100
8,078.86 +38.48 (+0.48%) Bitcoin USD
64,370.06 +126.65 (+0.20%) CMC Crypto 200
1,390.56 +7.98 (+0.58%)
CSL Limited (CMXHF)
- GlobeNewswire
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with p
- PR Newswire
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
- Simply Wall St.
CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock?
CSL's (ASX:CSL) stock is up by 1.2% over the past month. We wonder if and what role the company's financials play in...
